Search Results - "Van Dalfsen, Jill M"

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist by Nichols, David P, Morgan, Sarah J, Skalland, Michelle, Vo, Anh T, Van Dalfsen, Jill M, Singh, Sachinkumar Bp, Ni, Wendy, Hoffman, Lucas R, McGeer, Kailee, Heltshe, Sonya L, Clancy, John P, Rowe, Steven M, Jorth, Peter, Singh, Pradeep K

“…BackgroundLung infections are among the most consequential manifestations of cystic fibrosis (CF) and are associated with reduced lung function and shortened…”
Get full text

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial by Nichols, David P, Paynter, Alex C, Heltshe, Sonya L, Donaldson, Scott H, Frederick, Carla A, Freedman, Steven D, Gelfond, Daniel, Hoffman, Lucas R, Kelly, Andrea, Narkewicz, Michael R, Pittman, Jessica E, Ratjen, Felix, Rosenfeld, Margaret, Sagel, Scott D, Schwarzenberg, Sarah Jane, Singh, Pradeep K, Solomon, George M, Stalvey, Michael S, Clancy, John P, Kirby, Shannon, Van Dalfsen, Jill M, Kloster, Margaret H, Rowe, Steven M

“…The cystic fibrosis (CF) modulator drug, elexacaftor/tezacaftor/ivacaftor (ETI), proved highly effective in controlled clinical trials for individuals with at…”
Get full text

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis by Rowe, Steven M, Heltshe, Sonya L, Gonska, Tanja, Donaldson, Scott H, Borowitz, Drucy, Gelfond, Daniel, Sagel, Scott D, Khan, Umer, Mayer-Hamblett, Nicole, Van Dalfsen, Jill M, Joseloff, Elizabeth, Ramsey, Bonnie W

“…Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6 and older with the G551D…”
Get full text

Effect of Chronic Intermittent Administration of Inhaled Tobramycin on Respiratory Microbial Flora in Patients with Cystic Fibrosis by Burns, Jane L., Van Dalfsen, Jill M., Shawar, Ribhi M., Otto, Kelly L., Garber, Richard L., Quan, Joanne M., Montgomery, A. Bruce, Albers, Gary M., Ramsey, Bonnie W., Smith, Arnold L.

“…Pseudomonas aeruginosa endobronchial infection causes significant morbidity and mortality among cystic fibrosis patients. Microbiology results from two…”
Get full text

Highly Effective Cystic Fibrosis Clinical Research Teams: Critical Success Factors by Retsch-Bogart, George Z., Van Dalfsen, Jill M., Marshall, Bruce C., George, Cynthia, Pilewski, Joseph M., Nelson, Eugene C., Goss, Christopher H., Ramsey, Bonnie W.

“…ABSTRACT BACKGROUND Bringing new therapies to patients with rare diseases depends in part on optimizing clinical trial conduct through efficient study start-up…”
Get full text

Comparison of Two Culture Methods for Detection of Tobramycin-Resistant Gram-Negative Organisms in the Sputum of Patients with Cystic Fibrosis by VAN DALFSEN, Jill M, STAPP, Jenny R, PHELPS, Charles, STEWART, Patricia, BURNS, Jane L

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis? by VanDevanter, Donald R., Van Dalfsen, Jill M.

“…Recent studies suggest that chronic Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) involve anaerobic biofilms, and that these biofilms are the…”
Get full text

In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients by VanDevanter, Donald R., Van Dalfsen, Jill M., Burns, Jane L., Mayer-Hamblett, Nicole

“…Chronic antibiotic suppression of cystic fibrosis (CF) infections has increased in the United States, as has isolation of Pseudomonas aeruginosa with reduced…”
Get full text

A pipeline of therapies for cystic fibrosis by Ashlock, Melissa A, Beall, Robert J, Hamblett, Nicole M, Konstan, Michael W, Penland, Christopher M, Ramsey, Bonnie W, Van Dalfsen, Jill M, Wetmore, Diana R, Campbell, 3rd, Preston W

“…Therapeutics development for cystic fibrosis (CF) involves a coordinated effort among many groups, including individuals with CF and their caregivers, clinical…”
Get more information

Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Clinical Trial Study Design by Mayer-Hamblett, Nicole, Nichols, David P, Odem-Davis, Katherine, Riekert, Kristin A, Sawicki, Greg S, Donaldson, Scott H, Ratjen, Felix, Konstan, Michael W, Simon, Noah, Rosenbluth, Daniel B, Retsch-Bogart, George, Clancy, John P, VanDalfsen, Jill M, Buckingham, Rachael, Gifford, Alex H

“…The care for individuals with cystic fibrosis (CF) with at least one F508del mutation will greatly change as a result of the unparalleled clinical benefits…”
Get full text

Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor in G551 D-mediated Cystic Fibrosis by ROWE, Steven M, HELTSHE, Sonya L, JOSELOFF, Elizabeth, RAMSEY, Bonnie W, GONSKA, Tanja, DONALDSON, Scott H, BOROWITZ, Drucy, GELFOND, Daniel, SAGEL, Scott D, KHAN, Umer, MAYER-HAMBLETT, Nicole, VAN DALFSEN, Jill M

Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text

Authors' Reply by Van Devanter, Donald R., Van Dalfsen, Jill M.

Get full text